Ironwood Pharmaceuticals (IRWD)
(Delayed Data from NSDQ)
$6.72 USD
+0.09 (1.36%)
Updated Jul 19, 2024 04:00 PM ET
4-Sell of 5 4
C Value B Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IRWD 6.72 +0.09(1.36%)
Will IRWD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IRWD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IRWD
Implied Volatility Surging for Ironwood Pharmaceuticals (IRWD) Stock Options
New Strong Sell Stocks for July 5th
IRWD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates
Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q1 Earnings Expected to Decline
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
Other News for IRWD
Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday
Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC
Ironwood Pharma Elevates CFO and Repays Convertible Notes
Insider Sale: Director Julie Mchugh Sells Shares of Ironwood Pharmaceuticals Inc (IRWD)
Insider Sale: Director Catherine Moukheibir Sells 80,000 Shares of Ironwood Pharmaceuticals Inc ...